Myriad Genetics Inc. (MYGN) intrinsic value & 10-year financials
Myriad Genetics Inc. (MYGN) has a Graham intrinsic value of $0.56 per share. At $3.98 on Oct 17, 2026, the stock trades 611% above that value. Over the last 10 fiscal years revenue grew 1.2% a year to $824.5M, with an average return on invested capital of -11.5%.
- Graham intrinsic value
- $0.56
- Share price (Oct 17, 2026)
- $3.98
- Price vs Graham value
- 611% above
- Market cap
- $368.5M
- Revenue (FY2025)
- $824.5M
- Revenue growth (10-yr CAGR)
- 1.2%
- ROIC (10-yr avg)
- -11.5%
- Free cash flow (FY2025)
- -$13.8M
MYGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $824.5M | -$365.9M | -$3.95 | -$13.8M | -47.0% | -62.5% |
| FY2024 | $837.6M | -$127.3M | -$1.41 | -$27.7M | -14.7% | -16.3% |
| FY2023 | $753.2M | -$263.3M | -$3.18 | -$174.1M | -34.2% | -29.5% |
| FY2022 | $678.4M | -$112.0M | -$1.39 | -$151.6M | -20.7% | -12.8% |
| FY2021 | $690.6M | -$27.2M | -$0.35 | $200.0K | -27.6% | -10.4% |
| FY2020 | $638.6M | -$199.5M | -$2.69 | $50.5M | -36.3% | -18.3% |
| FY2019 | $851.1M | $4.6M | $0.06 | $75.1M | 0.9% | 0.7% |
| FY2018 | $772.6M | $131.1M | $1.82 | $107.5M | 15.4% | 14.5% |
| FY2017 | $769.9M | $21.8M | $0.32 | $100.1M | 6.4% | 3.2% |
| FY2016 | $740.5M | $125.3M | $1.71 | $161.3M | 22.5% | 16.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MYRIAD GENETICS INC has demonstrated mature, steady growth, with revenue compounding at 1.2% annually over the past decade.
MYRIAD GENETICS INC has historically struggled to out-earn its cost of capital, averaging just -11.5% ROIC.
MYRIAD GENETICS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MYRIAD GENETICS INC is modeled at 1.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.56 per share.